100% clinical reproducibility for the UltraGene Combo2Screen SARS-CoV-2 Assay on the QCMD panel!

We are pleased to announce that the UltraGene Combo2Screen SARS-CoV-2 Assay has been validated by the Quality Control for Molecular Diagnostics (QCMD). The QCMD is an independent International External Quality Assessment (EQA) / Proficiency Testing (PT) organisation, providing wide-ranging quality assessment services. This organisation primarily focuses on molecular infectious diseases. 

The UltraGene Combo2Screen SARS-CoV-2 Assay has demonstrated 100% clinical reproducibility.  The exceptional reproducibility validated by the External Quality Assessment Proficiency Testing, ensures the best possible performance for all front-line clinicians during the COVID-19 pandemic. ABL conducted a clinical validation and registered for the 2020 Coronavirus Outbreak Preparedness (CVOP) EQA Pilot Study (Ref# QAV204214_1) from QCMD which is composed of 8 tests.

ABL obtained 100% clinical reproducibility.